Childhood neuroblastoma is often a fatal disease. A new approach using a combination of two drugs shows promise in reducing ...

When Lauren and Joe Sewell welcomed their daughter Violette, they immediately suspected something was wrong, but doctors ...

Neuroblastoma is a solid tumor that occurs in children. When high-risk, the disease has a poor prognosis. Decades ago, adding ...

The long-term survival of a patient with neuroblastoma suggests the personalized cancer treatment may work for solid tumors, not just blood cancers.

A woman diagnosed with neuroblastoma in childhood has remained in remission for more than 18 years after being treated with an engineered CAR T-cell therapy at 4 years of age, according to follow ...

Neuroblastoma is a solid tumor that occurs in children. When high-risk, the disease has a poor prognosis.

Neuroblastoma is a solid tumor that occurs in children. When high-risk, the disease has a poor prognosis. Decades ago, adding the drug retinoic acid to neuroblastoma treatment increased survival by 10 ...

A new study published in Nature Communications heralded some fascinating findings on the future of drug development for neuroblastoma treatment.  Canc | Cancer ...

Sufficient funds have been raised to purchase the special medication needed for treating neuroblastoma (nerve cancer) for ...

The Phase 2 clinical trial demonstrated a 50% overall response rate, indicating statistically significant efficacy in treating relapsed/refractory high-risk neuroblastoma, which is a critical ...

Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and ...